NDLI: Small bowel adenocarcinoma - terra incognita: A demand for cross-national pooling of data

Content Provider	PubMed Central
Author	Schwameis, Katrin Schoppmann, Sebastian Friedrich Judith, Stift Michael, Schwameis Anton, Stift
Copyright Year	2014
Abstract	To date, due to the rarity, tumor biology and carcinogenesis of small bowel adenocarcinoma (SBA), the disease has been explored insufficiently and immunophenotyping and molecular characterization have not been finalized. This knowledge gap consecutively leads to an overt lack of diagnostic and therapeutic recommendations. In the current study, we provide our experience with the treatment of SBA, and demand for cross-national data pooling to enable unlimited information transfer and higher powered study. A comprehensive database of all patients with SBA was established and consecutively reviewed for clinicopathohistological data, information concerning preoperative evaluation, surgical and chemotherapeutical treatment, as well as outcome parameters. Patients underwent curative intended surgery (42.4%; n=14), adjuvant chemotherapy (CTX) following resection (36.4%; n=12) or palliative care (21.2%; n=7). The majority of patients were diagnosed at an advanced disease stage (pT3, 36.4%; pT4, 39.4%) and the duodenum was the most common tumor site (57.1%; n=20). Complete surgical resection was achieved in 88.5% of patients, while postoperative complications occurred in 19.4%. Within a mean follow-up period of 31.4 months, 17 patients succumbed to the disease following a median survival time of 11 months. Mean overall survival (OS) was 47.4, 25.3 and 9.8 months for surgically, surgically and chemotherapeutically and palliatively treated patients, respectively. Early surgical resection remains the mainstay in the treatment of localized SBA, since it is associated with a prolongation of OS. The role of neoadjuvant and adjuvant CTX has not yet been defined. Thus, since no consensus exists on the adequate treatment of these malignancies, we demand an international collaboration and cross-national data pooling to pave the way for the implementation of evidence-based standard care operating procedures.
Related Links	http://dx.doi.org/10.3892/ol.2014.1919
Starting Page	1613
File Format	PDF
ISSN	17921074
e-ISSN	17921082
Journal	Oncology Letters
Issue Number	5
Volume Number	7
Language	English
Publisher	D.A. Spandidos
Publisher Date	2014-02-01
Access Restriction	Open
Rights Holder	D.A. Spandidos
Subject Keyword	Cancer Research Oncology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Cetuximab in small bowel adenocarcinoma: a new friend?

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

Reply: Cetuximab in small bowel adenocarcinoma: a new friend?

Small bowel adenocarcinoma arising in a patient with hereditary hemorrhagic telangiectasia: A case report

Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis

Case Report: Molecular Features and Treatment Options for Small Bowel Adenocarcinoma

Development and validation of a nomogram for predicting cancer-specific survival in small-bowel adenocarcinoma patients using the SEER database

Cetuximab in small bowel adenocarcinoma: a new friend?

Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study

Small bowel adenocarcinoma - terra incognita: A demand for cross-national pooling of data

Similar Documents

Cetuximab in small bowel adenocarcinoma: a new friend?

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

Reply: Cetuximab in small bowel adenocarcinoma: a new friend?

Small bowel adenocarcinoma arising in a patient with hereditary hemorrhagic telangiectasia: A case report

Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis

Case Report: Molecular Features and Treatment Options for Small Bowel Adenocarcinoma

Development and validation of a nomogram for predicting cancer-specific survival in small-bowel adenocarcinoma patients using the SEER database

Cetuximab in small bowel adenocarcinoma: a new friend?

Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study

Small bowel adenocarcinoma - terra incognita: A demand for cross-national pooling of data